Research Articles

Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
stats4

Search for:

     Resmetirom
22 records.
Article ID PMID Source Title Publish Year
A00500 35060815 Expert Opin Investig Drugs Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. 2022 Details
A01057 34884910 Int J Mol Sci TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD. 2021 Details
A01853 34588764 Drug Des Devel Ther Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. 2021 Details
A03808 33860116 Hepatol Commun Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. 2021 Details
A04346 33655500 Br J Pharmacol Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. 2021 Details
A04749 33515800 Ann Hepatol Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. 2021 Details
A05080 33385317 J Dig Dis Efficacy and safety of drugs for nonalcoholic steatohepatitis. 2021 Details
A05309 33306682 PLoS One Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). 2020 Details
A05376 33278029 Pharmacotherapy Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. 2021 Details
A05793 33115209 Diabetes Metab J Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. 2020 Details
A06825 32733906 Front Med (Lausanne) Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders. 2020 Details
A08327 32151660 Metabolism Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. 2020 Details
A08469 32098589 Thyroid Thyroid Hormone Analogues: An Update. 2020 Details
A08581 32052857 Hepatology New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. 2020 Details
A09482 31727409 Lancet Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 2019 Details
A10083 31495973 Hepatol Res Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. 2019 Details
A29268 34329774 Clin Gastroenterol Hepatol Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. 2021 Details
A43317 31985310 Expert Opin Investig Drugs Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). 2020 Details
A43381 31868036 Expert Opin Investig Drugs Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). 2019 Details
A49230 35814516 J Clin Exp Hepatol Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis. 2022 Details
A50136 35507280 Curr Atheroscler Rep Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. 2022 Details
A51306 35735253 Hepatol Commun Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. 2022 Details